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Surveillance plays a pivotal role in overcoming antimi-
crobial resistance (AMR) in bacterial pathogens, and 
a variety of surveillance systems have been set up 
and employed in many countries. In 2015, the World 
Health Organization launched the Global Antimicrobial 
Resistance Surveillance System (GLASS) as a part of 
the global action plan to enhance national and global 
surveillance and research. The aims of GLASS are to 
foster development of national surveillance systems 
and to enable collection, analysis and sharing of 
standardised, comparable and validated data on AMR 
between different countries. The South Korean AMR 
surveillance system, Kor-GLASS, is compatible with 
the GLASS platform and was established in 2016 and 
based on the principles of representativeness, special-
isation, harmonisation and localisation. In this report, 
we summarise principles and processes in order to 
share our experiences with other countries planning 
to establish a national AMR surveillance system. The 
pilot operation of Kor-GLASS allowed us to understand 
the national burden of specific infectious diseases and 
the status of bacterial AMR. Issues pertaining to high 
costs and labour-intensive operation were raised dur-
ing the pilot, and improvements are being made.
Background
Antimicrobial resistance (AMR) in bacterial pathogens 
has become one of the most important threats to pub-
lic health around the world, resulting in high morbidity 
and mortality, prolonged hospitalisation and increased 
medical expenses [1]. In 2014, O’Neill et al. estimated 
that AMR will cause 10 million deaths and 100.2 trillion 
USD in losses per year in world gross domestic prod-
uct (GDP) by 2050 [2]. The World Health Organization 
(WHO) presented the global action plan on AMR in 
2015 [3], consisting of five strategic objectives: (i) to 
improve awareness and understanding of AMR; (ii) 
to strengthen knowledge through surveillance and 
research; (iii) to reduce the incidence of infection; (iv) 
to optimise the use of antimicrobial agents; and (v) to 
develop an economic case for sustainable investment 
that takes into account the needs of all countries and 
increases investment in new medicines, diagnostic 
tools, vaccines and other interventions.
Surveillance is one of the pivotal components neces-
sary to overcome AMR, and a variety of surveillance 
systems for humans have been set up in many coun-
tries [1]. A representative example is the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net) coordinated by the European Centre for Disease 
Control and Prevention [4]. The network collects har-
monised AMR data about invasive isolates from mem-
ber countries’ national AMR surveillance systems. 
However, there are many differences among surveil-
lance systems in terms of target microorganisms, target 
antimicrobial agents, monitoring methods, reporting 
methods, monitoring periods and so on [1]. These dif-
ferences make it difficult to compare and interpret AMR 
results from each surveillance system and to establish 
appropriate policies and plans to control AMR. In 2015, 
WHO launched the Global Antimicrobial Resistance 
Surveillance System (GLASS) [5] which allows ascer-
tainment of the most frequent type of AMR bacterial 
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infections, the age- and sex-structures of infections, 
infection types (community origin (CO), hospital origin 
(HO)), and therefore provides better understanding of 
the impact of AMR on human health.
The Korea Centers for Disease Control and Prevention 
(KCDC) operated a nationwide AMR surveillance sys-
tem (South Korean Antimicrobial Resistance Monitoring 
System, KARMS) between 2002 and 2015 [6-8]. The 
system collected laboratory data to monitor AMR and 
to detect emerging resistance from sentinel hospitals. 
However, issues regarding data reliability were raised 
for KARMS, resulting from differences in antimicro-
bial susceptibility testing methods and interpretation 
breakpoints by hospital. Insufficient deduplication 
of clinical isolates and data was also a problem. The 
Ministry of Health and Welfare of South Korea released 
a National Action Plan in 2016 [9] including the estab-
lishment of a new national AMR surveillance sys-
tem, Kor-GLASS, which is compatible with the GLASS 
platform. This new system is based on the collection 
of non-duplicate clinical isolates and data by speci-
men from sentinel hospitals. The collected isolates are 
characterised in an analysis centre with a standardised 
method allowing harmonised data.
South Korea is currently experiencing challenges with 
AMR. The most recent KARMS report stated that met-
icillin-resistant  Staphylococcus aureus  is common (ca. 
66% of  S. aureus), and among tested  Acinetobacter 
baumannii  and  Pseudomonas aeruginosa  isolates 
collected from 16 general hospitals (intensive care and 
general wards) in 2015, 85% and 35% tested were imi-
penem-resistant positive, respectively [8]. The estab-
lishment of Kor-GLASS is one of the ways in which 
South Korea is tackling the problem. In this article, we 
summarise principles and processes established for 
Kor-GLASS in order to share our experiences with other 
countries planning to establish a national AMR surveil-
lance system.
Figure 1
Structure and governance of the national antimicrobial resistance surveillance system Kor-GLASS, South Korea
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Setting and structure of Kor-GLASS
South Korea is an urbanised country with a popula-
tion of 51.02 million and GDP per capita of 23,306 EUR 
(27,097 USD) in 2015 [10], making South Korea’s GDP 
the 30th highest in the world. The medical system is 
composed mainly of private medical institutions, and 
the proportion of hospital beds in public medical insti-
tutions (10.4%) is low. Hospitals are categorised as 
primary (n = 32,268), secondary (n = 301), and tertiary 
care (n = 43). Primary-care hospitals have outpatients 
only, while secondary- and tertiary-care hospitals have 
both outpatients and inpatients.
The structure of Kor-GLASS has been designed in 
accordance with the four principles of representative-
ness, specialisation, harmonisation and localisation. 
Kor-GLASS was set up and is governed by the KCDC.
Representativeness
The KCDC: (i) established the structure; (ii) funds the 
study; (iii) governs the system; and (iv) operates the 
national coordinating centre (Division of Infectious 
Disease Surveillance), the national focal point (Division 
of Healthcare-Associated Infection Control) and the 
national reference laboratory (Division of Antimicrobial 
Resistance) (Figure 1).
The system has been designed to collect and analyse 
complete non-duplicate clinical isolates and informa-
tion from six sentinel hospitals (each with a capacity 
of between 655 and 1,000 beds) caring for both inpa-
tients and outpatients (Figure 1), representing four of 
nine provinces and two of seven metropolitan cities in 
South Korea (Supplementary Figure 1). The population 
covered by each sentinel hospital ranges from 1.55 to 
12.71 million.
Figure 2
Schematic flow of collection, transfer, analysis and storage of clinical isolates in the national antimicrobial resistance 
surveillance system Kor-GLASS, South Korea
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Specialisation
Kor-GLASS has operational and advisory committees 
consisting of members with expertise in infectious 
disease and clinical microbiology in South Korea. 
Clinical isolates and information collected through 
the system are scrutinised in an analysis centre with 
both hard- and software appropriate for AMR study. 
The capability of the diagnostic microbiologic labora-
tories of sentinel hospitals to produce accurate and 
reproducible data was another consideration. The sen-
tinel hospitals were selected according to the criteria 
of having: (i) an occupational clinical microbiologist; 
(ii) a clinical microbiology laboratory certified by both 
the Quality Assessment programme and the External 
Quality Control programme in South Korea [11]; and (iii) 
a laboratory information system and electronic medical 
record service to ease epidemiological data collection.
Harmonisation
All isolates collected are transferred to the analysis 
centre and assessed together for AMR pheno- and 
genotyping and strain typing for molecular epidemiol-
ogy using harmonised testing methods, using a format-
ted clinical data collection system. Bacterial collection 
guidelines by specimen including isolation, storage 
and transfer are shared with sentinel hospitals, and 
educational programmes for laboratory personnel are 
held twice a year. Clinical data including infection origin 
(CO and HO), age, sex and admission types (outpatient, 
inpatient in general ward or intensive care unit) are col-
lected for all patients for whom blood, urine, stool and 
urethral/cervical discharge have been cultured, regard-
less of culture positivity or negativity. Infection origins 
are categorised according to the number of hospitali-
sation days at the time of specimen sampling: HO, if 
the specimen was taken at ≥ 2 calendar days of hospi-
talisation including the days hospitalised in a previous 
healthcare facility before transfer; CO, if the specimen 
was taken either from an outpatient or from an inpa-
tient of < 2 calendar days of hospitalisation. The data 
are further used to analyse the AMR burden in patients 
admitted to sentinel hospitals.
Localisation
To reflect South Korean AMR traits, the GLASS manual 
has been customised as follows: (i) three additional 
target pathogens were included:  Enterococcus fae-
calis,  E. faecium, and  P. aeruginosa  blood isolates to 
Table 1
Molecular characterisation of AMR determinants and strain types, national antimicrobial resistance surveillance system 
Kor-GLASS, South Korea
Species AMR determinants Epidemiological markers
Staphylococcus aureus
• Meticillin-resistance gene PCR (mecA/mecC) 
 
• SCCmec typing 
 
• agr polymorphism typing
• MLST 
 
• spa-typing
Enterococcus faecalis 
 
E. faecium
• Glycopeptide-resistance gene PCR (vanA/vanB/vanM) 
 
• Tn1546 analysis
• MLST 
 
• Plasmid analysis 
 
(replicon typing)
Escherichia coli 
 
Klebsiella pneumoniae
• ESBL gene PCR and sequencing 
(blaCTX-M-1, blaCTX-M-9, blaCTX-M-2, blaCTX-M25, blaTEM, blaSHV) 
 
• AmpC β-lactamase PCR and sequencing 
(blaDHA, blaCMY-1, blaCMY-2, blaACT, blaACC, blaFOX) 
 
• Carbapenemase gene PCR and sequencing 
(blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP, blaGES) 
 
• Mobile colistin resistance gene PCR (mcr-1/-2)
• MLST 
 
• Plasmid analysis 
 
(replicon typing)
Pseudomonas aeruginosa      Carbapenemase gene PCR and sequencing (blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP, blaGES)
• Class 1 integron 
 
• MLST
Acinetobacter spp. • Carbapenemase PCR and sequencing (blaOXA-23/-24/-51/-58, blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP, blaGES)
• Transposon 
 
• MLST
Salmonella spp. 
 
Shigella spp.
• CTX-M ESBL PCR and sequencing 
(blaCTX-M-1, blaCTX-M-9, blaCTX-M-2, blaCTX-M-25) 
 
• Fluoroquinolone resistance gene PCR and sequencing (repA, 
gyrA, parC)
     NA
Neisseria gonorrhoeae
• Cephalosporin-resistance gene analysis (penA) 
 
• Spectinomycin-resistance gene PCR and sequencing (16S 
rRNA, rpsE, 23S rRNA) 
 
• Azithromycin-resistance gene PCR (ermB, ermC, ermF, mef )
• NG-MAST 
 
• MLST
AMR: antimicrobial resistance; ESBL: extended-spectrum beta-lactamase; MLST: multilocus sequence typing; NA: not applicable; NG-
MAST: Neisseria gonorrhoeae multi-antigen sequence typing.
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monitor the glycopeptide and carbapenem resistance 
critical in South Korean clinical settings; (ii) further tar-
get antimicrobials to categorise multi-drug resistance 
were added, so in the case of  S. aureus, for example, 
we tested not only cefoxitin as in the GLASS manual, 
but also erythromycin, clindamycin, co-trimoxazole, 
quinupristin-dalfopristin, mupirocin, vancomycin, 
teicoplanin, linezolid and tigecycline; and (iii) auxiliary 
genetic analysis to understand the extent of resist-
ance determinants in South Korean clinical settings 
and strain typing to assess molecular epidemiology of 
drug-resistant clones dominant in the country.
 
Operating manual for handling samples 
within Kor-GLASS
There are four steps within Kor-GLASS: collection and 
transfer of clinical isolates, basic characterisation, 
advanced characterisation and long-term storage 
(Figure 2). 
Collection and transfer of clinical isolates
The target pathogens in Kor-GLASS are  S. 
aureus,  Streptococcus pneumoniae, E. faecalis, E. 
faecium, Escherichia coli, Klebsiella pneumoniae, P. 
aeruginosa, A. baumannii, and  Salmonella  species 
recovered from blood specimens;  Salmonella  and  S
higella  species from stool specimens;  E. coli  and  K. 
pneumoniae from urine specimens; and Neisseria gon-
orrhoeae  from urethral/cervical discharge specimens. 
All isolates of target pathogens from target specimens 
are collected in each sentinel hospital. Clinical isolates 
are recovered through enrichment culture for blood 
specimens, selective cultures for stool and urethral/
cervical discharge specimens. For urine specimens, 
semi-quantitative culture is carried out to judge if the 
isolate meets the following criteria: (i) ≥ 104  CFU/mL 
single-species growth of either  E. colior  K. pneumo-
niae or (ii) ≥  105 CFU/mL of E. coli or K. pneumoniae  in 
growth of mixed species [12]. Each isolate is inoculated 
into two cryotubes containing 20% (w/v) skimmed milk 
[13]: one for long-term storage at −  80 °C in each sen-
tinel hospital and the other for transfer to the analysis 
centre. Bacterial isolate transfer is carried out twice a 
month, maintaining the cold chain. For the transferred 
clinical isolates, purity and viability are verified by 
sub-culture. If an isolate does not grow or has been 
contaminated, the sentinel hospitals are asked to re-
send the isolate. Feedback is given in case of contami-
nation and no growth to improve the performance in 
sentinel hospitals.
Basic characterisation of collected isolates 
and reporting
Bacterial species of the collected isolates are verified 
using Matrix-Assisted Laser Desorption/Ionization 
Time-of-Flight (MALDI-TOF) mass spectrometry (Bruker 
Biotyper, Bruker Daltonics GmbH, Bremen, Germany) in 
the analysis centre.  Acinetobacter  species are identi-
fied with a species-specific PCR targeting blaOXA-51 and 
with rpoB gene sequencing [14]. Species identification 
discrepancy between a sentinel hospital and the anal-
ysis centre is confirmed by 16S rDNA sequencing [15] 
and feedback is given. Antimicrobial susceptibility is 
mainly determined by the disk diffusion test following 
the Clinical and Laboratory Standards Institute (CLSI) 
guidelines revised in 2016 (M100-S26) [16]. Etest, 
agar dilution and broth microdilution tests are also 
employed in cases where disk diffusion is unavailable 
or minimum inhibitory concentration (MIC) is needed for 
further analysis (Supplementary Table 1). Colistin MIC 
is determined by the broth microdilution method fol-
lowing the recommendations of the joint CLSI-EUCAST 
Polymyxin Breakpoints Working Group [17]. Images 
from disk diffusion and Etest are stored for checking 
data-entry mistakes. Blind cross-checks for antimicro-
bial susceptibility testing between the analysis centre 
and the national reference laboratory are also carried 
out on a monthly basis to validate the results. Third-
party verification is made for any discrepancy and a 
correction is made following the recommendations of 
the advisory committee. Basic characterisation of the 
collected isolates in the analysis centre takes ca 2 
months. The national focal point collects the results 
of basic characterisation integrated with clinical data 
monthly and the national coordinating centre reports 
Kor-GLASS’s results to WHO annually.
Advanced characterisation of collected 
isolates
The analysis centre performs advanced characterisa-
tion, including AMR genotyping and strain typing, to 
assess the molecular epidemiological characteris-
tics of major pathogens. AMR genotyping is done for 
methicillin resistance in  S. aureus, vancomycin resist-
ance in enterococci, third- and fourth-generation 
cephalosporin, carbapenem and colistin resistance in 
Gram-negative bacilli (Table 1). SCCmec typing for meti-
cillin-resistant S. aureus is also performed by multiplex 
PCR as described previously [18]. Multilocus sequence 
typing (MLST) is carried out following species-specific 
methods and  agr  and  spa-typing is performed for  S. 
aureus  as described previously [19]. Advanced char-
acterisation of the collected isolates in the analysis 
centre takes an additional 2 months. The national focal 
point collects aggregated results monthly from the 
analysis centre.
Long-term storage of collected isolates
Four cryotubes containing each isolate in 20% 
skimmed milk are created in the analysis centre: two 
for storage in the national reference laboratory for fur-
ther construction of a national bank for AMR strains, 
one for long-term storage in the analysis centre and the 
other for working stock. Eventually, each isolate is kept 
independently at three separate sites: one in the senti-
nel hospital, two in the analysis centre and two in the 
national reference laboratory.
Budget for Kor-GLASS
The budget consists of analysis costs and collection 
and transfer costs. The cost for analysis was calculated 
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using the number of isolates collected during Kor-
GLASS’s pilot in 2016, multiplied by unit cost of each 
test (Table 2). The average of unit cost for analysing 
each isolate was 57 EUR (71 USD) for blood isolates, 
ranging from 22 to 164 EUR (28–206 USD), depending 
on the species; 21 EUR (27 USD) for urine isolates and 
29 EUR (36 USD) for stool isolates. The total cost for 
analysis of 110,911 isolates collected was 631,077 EUR 
(788,854 USD): 468,996 EUR (586,251 USD) for blood 
isolates (n = 3,523); 159,833 EUR (199,792 USD) for 
urine isolates (n = 7,491); and 2,248 EUR (2,811 USD) for 
stool isolates (n = 77). The cost for collection and trans-
fer per sentinel hospital was 32,000 EUR (40,000 USD) 
and, multiplied by the six sentinel hospitals, the total 
cost was 192,000 EUR (240,000 USD). The total budget 
to run the system was 823,077 EUR (1,028,854 USD).
Table 2
Budget for the analysis centre of the national antimicrobial resistance surveillance system Kor-GLASS, South Korea, pilot 
year, May 2016 to April 2017
Specimen Species Number of isolates
Cost in EUR (USD)
Identification Disk diffusion Etest
Agar 
dilution PCR
Genotypic 
 
sequencing
MLST Average 
cost 
 
/isolate
Total
6 (7.4) 
 
/isolate
0.8 (1) 
 
/disk
2.4 (3) 
 
/strip
16 (20) /
isolate
8 (10) 
 
/reaction
8 (10) 
 
/gene
80 (100) 
 
/isolate
Blood 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
Staphylococcus 
aureus 584
3,504 
 
(4,380)
2,803 
 
(3,504)
5,606 
 
(7,008)
NT
37,376 
 
(46,720)
NT
46,720 
 
(58,400)
164 
 
(206)
96,009 
 
(120,012)
Streptococcus. 
pneumoniae 28
168 
 
(210)
NT NT
448a 
 
(560)a
NT NT NT
22 
 
(28)
616 
 
(770)
Enterococcus 
faecalis 161
966 
 
(1,208)
644 
 
(805)
1,546 
 
(1,933)
NT
2,576 
 
(3,220)
NT
12,880 
 
(16,100)
116 
 
(145)
18,612 
 
(23,266)
E. faecium 217
1,302 
 
(1,628)
1,042 
 
(1,303)
2,083 
 
(2,604)
NT
3,472 
 
(4,340)
NT
17,360 
 
(21,700)
116 
 
(145)
25,259 
 
(31,575)
Escherichia coli 1,536
9,216 
 
(11,520)
23,347 
 
(29,184)
NT
246 
 
(308)
30,259 
 
(37,824)
9,062 
 
(11,328)
122,880 
 
(153,600)
127 
 
(159)
195,010 
 
(243,764)
Klebsiella 
pneumoniae 597
3,582 
 
(4,478)
8,597 
 
(10,746)
NT
478 
 
(598)
15,761 
 
(19,701)
4,716 
 
(5,895)
47,760 
 
(59,700)
136 
 
(169)
80,894 
 
(101,118)
Salmonella spp. 44
264 
 
(330)
NT NT
704b 
 
(880)b
176 
 
(220)
141 
 
(176)
NT
29 
 
(36)
1,285 
 
(1,606)
Pseudomonas 
aeruginosa 127
762 
 
(953)
1,118 
 
(1,398)
NT
406 
 
(508)
1,829 
 
(2,286)
305 
 
(381)
10,160 
 
(12,700)
115 
 
(143)
14,580 
 
(18,226)
Acinetobacter spp. 229
1,374 
 
(1,718)
2,564 
 
(3,205)
NT
2,931 
 
(3,664)
9,893 
 
(12,366)
1,649 
 
(2,061)
18,320 
 
(22,900)
160 
 
(200)
36,731 
 
(45,914)
Subtotal 3,523
21,138 
 
(26,425)
40,115 
 
(50,145)
9,235 
 
(11,545)
5,213 
 
(6,518)
101,342 
 
(126,677)
15,873 
 
(19,841)
276,080 
(345,100)
133 
 
(166)
468,996 
 
(586,251)
Urine 
 
  
 
 
E. coli 6,394
38,364 
 
(47,955)
97,189 
 
(121,486)
NT
1,023 
 
(1,279)
NT NT NT
21 
 
(27)
136,576 
 
(170,720)
K. pneumoniae 1,097
6,582 
 
(8,228)
15,797 
 
(19,746)
NT
878 
 
(1,098)
NT NT NT
21 
 
(27)
23,257 
 
(29,072)
Subtotal 7,491
44,946 
 
(56,183)
112,986 
 
(141,232)
NT
1,901 
 
(2,377)
NT NT NT
21 
 
(27)
159,833 
 
(199,792)
Stool Salmonella spp. 77
462 
 
(578)
NT NT
1,232b 
 
(1,540)b
308 
 
(385)
246 
 
(308)
NT
29 
 
(36)
2,248 
 
(2,811)
Total 11,091
66,546 
 
(83,186)
153,101 
 
(191,377)
9,235 
 
(11,545)
8,346 
 
(10,435)
101,650 
 
(127,062)
16,119 
 
(20,149)
276,080 
(345,100)
57 
 
(71)
631,077 
 
(788,854)
MLST: multilocus sequence typing; NT: not tested.
a Costs for each test are rounded up to the nearest EUR.
b Antimicrobial susceptibilities of S. pneumoniae and Salmonella species were all tested by the broth microdilution method.
Exchange rate of 1 EUR = 1.25 USD applied.
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Pilot operation of Kor-GLASS
Kor-GLASS began operation on 1 May 2016, and ca 
1,000 isolates were collected each month for the first 
12 months. Although operational and advisory commit-
tees took charge of designing Kor-GLASS, several oper-
ating issues were raised.
First,  Shigella  species and  N. gonorrhoeae  causing 
CO infections were not isolated from the sentinel 
hospitals. Shigellosis had been the dominant acute 
bacterial gastroenteritis in South Korea until the 
1970s, but prevalence declined from the late 1980s 
and was rare by the 2010s [20]. Gonorrhoea is com-
mon in South Korea, and ca 15,000 cases are reported 
every year. More than 95% of patients with gonor-
rhoea in South Korea are diagnosed at primary care 
clinics [21]. Therefore, another surveillance system 
that included primary care clinics specialising in gon-
orrhoea was needed to monitor  N. gonorrhoeae  AMR. 
Secondly, although the sentinel hospitals operated the 
EMR system, it was very burdensome for laboratory 
personnel to collect the clinical data. Discriminating 
between CO and HO infections was another challenge 
due to difficulties in researching hospitalisation days 
in a previous healthcare facility before transfer. Thirdly, 
the analysis centre found the workload of the regular 
report and the characterisation of a huge collection 
to be very heavy. The number of laboratory personnel 
in the analysis centre doubled, from eight to 16, in 1 
year. Finally, discrepancies between AMR phenotypes 
and genotypes were identified. For instance, a 
few Enterobacteriaceae clinical isolates exhibiting 
extended-spectrum beta-lactamase (ESBL) or carbap-
enemase phenotypes did not carry any known ESBL 
or carbapenemase genes, and further analysis for the 
novel resistance determinants was needed.
Future plans for Kor-GLASS
Following the pilot study phase, Kor-GLASS is now 
expanding: (i) coverage is being enlarged by recruit-
ing further sentinel hospitals in districts not yet cov-
ered, including hospitals for long-term care, and by 
adding research targets (uncovered bacterial patho-
gens, recently launched antimicrobials, and emerg-
ing AMR determinants); (ii) a quality control centre 
is being established for quality improvement; (iii) an 
AMR bacterial bank is being constructed to enable the 
use of clinical isolates for further research; (iv) help-
ing the general public better understand the antimi-
crobial resistance surveillance system by creating an 
accessible and informative website; and (v) interna-
tional cooperation with multiplex networks not only 
with Asian countries but also with countries in other 
continents through hosting international symposiums 
and running an educational programme for developing 
countries through the Korea International Cooperation 
Agency.
Conclusion
South Korea is currently experiencing many problems 
and challenges from AMR. Kor-GLASS is realiable, 
with scalability, and capability for better performance. 
Beyond monitoring AMR, this system is a useful tool for 
public health authorities to deal with AMR. Kor-GLASS’s 
successful AMR monitoring system has encouraged the 
South Korean government to establish a ‘one health’ 
approach for AMR in 2017 and to further develop the 
project by 2019 [22,23].
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